F-Star Therapeutics Gets Fourth Option From Merck KGaA Affiliate
05 Janeiro 2022 - 10:57AM
Dow Jones News
By Chris Wack
F-star Therapeutics Inc. said Wednesday that Ares Trading SA, an
affiliate of Merck KGaA, has exercised a fourth licensing option to
develop another bispecific program under the ongoing
immuno-oncology collaboration.
Under the terms of the agreement, Merck KGaA would be
responsible for all future development and commercialization costs
and would pay future success-based milestones and royalties on any
net sales, resulting from programs covered by the agreement.
In May 2019, Merck KGaA exercised its option to bring a first
program from the collaboration into its pipeline. In July 2020,
Merck KGaA took an early option to a second program and in March
2021, a third option was exercised. With the fourth option now
exercised, the total potential remaining milestone-based revenue
due to F-star from this immuno-oncology collaboration with Merck
KGaA is $765 million.
F-star Therapeutics shares were up 5%, to $5.20, in premarket
trade.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 05, 2022 08:42 ET (13:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024